Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer?
- PMID: 34015310
- DOI: 10.1016/S1470-2045(21)00261-8
Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer?
Conflict of interest statement
BS reports consulting fees from Bristol Myers Squibb and speaker fees from AstraZeneca. TC reports consulting fees from MedImmune/AstraZeneca and Bristol Myers Squibb; advisory role fees from Bristol Myers Squibb, MedImmune/AstraZeneca, and EMD Serono; and clinical research funding to MD Anderson Cancer Center from Boehringer Ingelheim, MedImmune/AstraZeneca, EMD Serono, and Bristol Myers Squibb.
Comment on
-
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.Lancet Oncol. 2021 Jun;22(6):824-835. doi: 10.1016/S1470-2045(21)00149-2. Epub 2021 May 18. Lancet Oncol. 2021. PMID: 34015311 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
